Compare Medpace Holdings Inc (MEDP) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Short Term Corporate Bond ETF — how do they compare? Medpace Holdings Inc trades at $530.31 (market cap $15.08B), while Vanguard Short Term Corporate Bond ETF trades at $78.59. The key difference: Medpace Holdings Inc is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| MEDP | VCSH | |
|---|---|---|
Market Cap | $15.08B | — |
Sector | Technology | Fixed Income |
52-Week High | $620.59 | $80.20 |
52-Week Low | $308.88 | $78.45 |
Enterprise Value | $14.55B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
VCSH trades at $78.64, down 0.1% on the day, with a bearish technical signal driven by moving averages. The ETF maintains a steady dividend payout, with recent distributions of $0.29-$0.30 per share. News highlights institutional activity, including Allspring Global Investments purchasing 1.47 million shares in July 2026. The fund's focus on short-term corporate bonds offers a higher yield compared to treasury alternatives, though it carries greater credit risk.
The outlook for VCSH is mixed, balancing income appeal against interest rate sensitivity. Opportunities include attractive yield and low expense ratio, while risks involve Fed policy uncertainty and credit spread volatility. Investors seeking short-duration corporate exposure may find value, but should monitor rate expectations and economic conditions closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Short Term Corporate Bond ETF
VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.
Read more on VCSH →
